Loading…
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $48M | $-158M | $-170M | $-171M | 138.8% | -57.7% | - |
| 2024 | $115M | $-40M | $-57M | $-3M | -191.7% | - | - |
| 2023 | $0M | $-162M | $-180M | $-159M | -286.5% | - | - |
| 2022 | $0M | $-211M | $-229M | $-188M | -1899.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 114.70 | 48.47 |
| Operating Expense | 218.53 | 173.76 | 174.62 | 211.72 |
| Operating Income | -218.53 | -173.76 | -59.92 | -163.25 |
| EBITDA | -211.07 | -161.92 | -39.97 | -158.47 |
| EBIT | -215.50 | -166.31 | -44.12 | -159.47 |
| Pretax Income | -229.38 | -179.82 | -55.63 | -170.46 |
| Tax Provision | 0 | 0 | 0.89 | -0.09 |
| Net Income | -229.38 | -179.82 | -56.53 | -170.37 |
| Net Income Common Stockholders | -229.38 | -179.82 | -56.53 | -170.37 |
| Total Expenses | 218.53 | 173.76 | 174.62 | 211.72 |
| Interest Expense | 13.88 | 13.51 | 11.52 | 10.99 |
| Interest Income | 1.58 | 2 | 1.78 | 1.97 |
| Research And Development | 170.92 | 135.30 | 138.49 | 174.09 |
| Selling General And Administration | 47.61 | 38.45 | 36.13 | 37.63 |
| Normalized EBITDA | -211 | -151.92 | -39.97 | -150.99 |
| Normalized Income | -229.31 | -169.82 | -56.53 | -162.90 |
| Basic EPS | -2.71 | -1.18 | -0.25 | -0.75 |
| Diluted EPS | -2.71 | -1.18 | -0.25 | -0.75 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0 |
| Total Unusual Items | -0.07 | -10 | 0 | -7.47 |
| Total Unusual Items Excluding Goodwill | -0.07 | -10 | 0 | -7.47 |
| Net Income From Continuing Operation Net Minority Interest | -229.38 | -179.82 | -56.53 | -170.37 |
| Reconciled Depreciation | 4.43 | 4.38 | 4.15 | 1 |
| Net Interest Income | -12.30 | -11.51 | -9.74 | -9.02 |
| Net Income From Continuing And Discontinued Operation | -229.38 | -179.82 | -56.53 | -170.37 |
| Total Operating Income As Reported | -218.59 | -183.76 | -59.92 | -170.73 |
| Diluted Average Shares | 84.57 | 152.62 | 226.23 | 228.52 |
| Basic Average Shares | 84.57 | 152.62 | 226.23 | 228.52 |
| Diluted NI Availto Com Stockholders | -229.38 | -179.82 | -56.53 | -170.37 |
| Net Income Including Noncontrolling Interests | -229.38 | -179.82 | -56.53 | -170.37 |
| Net Income Continuous Operations | -229.38 | -179.82 | -56.53 | -170.37 |
| Other Income Expense | 1.45 | 5.46 | 14.02 | 1.81 |
| Other Non Operating Income Expenses | 1.51 | 15.46 | 14.02 | 9.29 |
| Special Income Charges | -0.07 | -10 | 0 | -7.47 |
| Other Special Charges | 0.07 | 10 | 0 | 7.47 |
| Net Non Operating Interest Income Expense | -12.30 | -11.51 | -9.74 | -9.02 |
| Interest Expense Non Operating | 13.88 | 13.51 | 11.52 | 10.99 |
| Interest Income Non Operating | 1.58 | 2 | 1.78 | 1.97 |
| General And Administrative Expense | 47.61 | 38.45 | 36.13 | 37.63 |
| Other Gand A | 47.61 | 38.45 | 36.13 | 37.63 |
| Operating Revenue | 0 | 0 | 114.70 | 48.47 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Gossamer Bio, Inc.this co. | GOSS | $82M | - | -0.67 | 138.8% | -0.91 |
| Health Catalyst, Inc. | HCAT | $93M | - | 0.37 | -72.4% | -32.70 |
| Aldeyra Therapeutics, Inc. | ALDX | $90M | - | 2.04 | -76.5% | -1.02 |
| MaxCyte, Inc. | MXCT | $87M | - | 0.51 | -26.0% | -0.06 |
| biote Corp. | BTMD | $83M | 3.00 | -1.16 |
| -53.7% |
| 4.32 |
| Outset Medical, Inc. | OM | $77M | - | 0.60 | -64.3% | -0.14 |
| aTyr Pharma, Inc. | ATYR | $75M | - | 1.11 | -110.2% | -0.11 |
| DocGo Inc. | DCGO | $70M | - | 0.48 | -144.9% | -0.41 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| Peer Median | - | 3.00 | 0.55 | -74.5% | -0.14 | |